Biweekly Cabazitaxel Is a Safe Treatment Option for Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients After Docetaxel - A Final Analysis of the Prosty II Trial
Year of publication
2020
Authors
Kellokumpu-Lehtinen, Pirkko-Liisa;Kellokumpu-Lehtinen, Pirkko-Liisa;Kellokumpu-Lehtinen, Pirkko-Liisa;Marttila, Timo;Jekunen, Antti;Hervonen, Petteri;Klintrup, Katariina;Kataja, Vesa;Utriainen, Tapio;Luukkaa, Marjaana;Leskinen, Markku;Pulkkanen, Kalevi;Kautio, Anna-Liisa;Huttunen, Teppo
Show moreOrganizations and authors
Helsinki University Hospital Catchment Area
Utriainen Tapio
Oulu University Hospital Catchment Area
Klintrup Katariina
Tampere University Hospital Catchment Area
Kautio Anna-Liisa
Leskinen Markku
Hervonen Petteri
Kellokumpu-Lehtinen Pirkko-Liisa
Marttila Timo
University of Helsinki
Utriainen Tapio
University of Turku
Jekunen Antti
Tampere University
Kellokumpu-Lehtinen Pirkko-Liisa
Publication type
Publication format
Article
Parent publication type
Journal
Article type
Original article
Audience
ScientificPeer-reviewed
Peer-ReviewedMINEDU's publication type classification code
A1 Journal article (refereed), original researchPublication channel information
Journal
Parent publication name
Volume
40
Issue
12
Pages
6915-6921
ISSN
Publication forum
Publication forum level
1
Open access
Open access in the publisher’s service
Yes
Open access of publication channel
Partially open publication channel
Self-archived
Yes
Other information
Fields of science
General medicine, internal medicine and other clinical medicine; Cancers
Keywords
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Internationality of the publisher
International
Language
English
International co-publication
No
Co-publication with a company
Yes
DOI
10.21873/anticanres.14715
The publication is included in the Ministry of Education and Culture’s Publication data collection
Yes